Compare Citius Pharmaceuticals Inc (CTXR) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Simon Property Group Inc trades at $199.81 (market cap $64.59B). The key difference: Simon Property Group Inc is far larger — about 4742.3× Citius Pharmaceuticals Inc's market cap, and Simon Property Group Inc pays a 4.46% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Simon Property Group Inc for 99 Days on average.
| CTXR | SPG | |
|---|---|---|
Market Cap | $13.62M | $64.59B |
Volume | 132,438 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $236.70 |
52-Week Low | $0.48 | $173.35 |
Typical Hold Time | 16 Days | 99 Days |
Enterprise Value | $3.79M | $93.03B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Simon Property Group (SPG) trades at $197.59, down 2.06% amid bearish technical signals, though fundamentals remain strong with robust profitability margins (net income margin 66.57%) and consistent revenue growth. Recent Q2 2026 earnings missed expectations, but Q4 2025 and Q1 2026 beat estimates. The company maintains solid cash flow from operations ($4.14B in 2025) and a raised dividend, while facing headwinds from rising bond yields and debt maturities.
Outlook: SPG offers value with a P/E of 14.09 below sector averages and a 42% analyst buy rating, targeting 13% upside to consensus. Risks include interest rate sensitivity, high leverage ($24.21B debt), and retail sector volatility. The stock's current pullback may present a buying opportunity for income investors, supported by strong leasing demand and strategic initiatives like the Simon Media Network launch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
